These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16842956)

  • 21. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):147-9. PubMed ID: 15183865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia.
    Chenoweth CE; Saint S; Martinez F; Lynch JP; Fendrick AM
    Mayo Clin Proc; 2000 Nov; 75(11):1161-8. PubMed ID: 11075746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Streptococcus pneumoniae and beta-lactam antibiotic agents].
    Ranin L; Vucković-Opavski N; Berger-Jekić O
    Srp Arh Celok Lek; 1996; 124(1-2):18-23. PubMed ID: 9102809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of pneumococcal pneumonia.
    Pallares R
    Semin Respir Infect; 1999 Sep; 14(3):276-84. PubMed ID: 10501315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults.
    Korsgaard J; Møller JK; Kilian M
    Int J Infect Dis; 2005 Sep; 9(5):274-9. PubMed ID: 16095941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the burden of pneumococcal disease in adults.
    Blasi F; Mantero M; Santus P; Tarsia P
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():7-14. PubMed ID: 22882668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
    Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will reduction of antibiotic use reduce antibiotic resistance?: The pneumococcus paradigm.
    Dagan R; Barkai G; Leibovitz E; Dreifuss E; Greenberg D
    Pediatr Infect Dis J; 2006 Oct; 25(10):981-6. PubMed ID: 17006311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.
    Picazo JJ
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():4-6. PubMed ID: 19366362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.
    Daneman N; Low DE; McGeer A; Green KA; Fisman DN
    Clin Infect Dis; 2008 Apr; 46(8):1131-8. PubMed ID: 18444846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
    Anderson KB; Tan JS; File TM; DiPersio JR; Willey BM; Low DE
    Clin Infect Dis; 2003 Aug; 37(3):376-81. PubMed ID: 12884162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antimicrobial resistance profile of Streptococcus pneumoniae.
    Reinert RR
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():7-11. PubMed ID: 19366363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
    Bhavnani SM; Hammel JP; Jones RN; Ambrose PG
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):31-7. PubMed ID: 15629226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.